Skip to main content
Top
Published in: Urolithiasis 2/2017

01-04-2017 | Original Paper

Should metabolic evaluation be performed in patients with struvite stones?

Authors: Muhammad Waqas Iqbal, Richard H. Shin, Ramy F. Youssef, Adam G. Kaplan, Fernando J. Cabrera, Jonathan Hanna, Charles D. Scales Jr., Michael N. Ferrandino, Glenn M. Preminger, Michael E. Lipkin

Published in: Urolithiasis | Issue 2/2017

Login to get access

Abstract

Previous studies suggested that patients with pure struvite calculi rarely have underlying metabolic abnormalities. Therefore, most of these patients do not undergo metabolic studies. We report our experience with these patients and their response to directed medical therapy. Between 1/2005 and 9/2012, 75 patients treated with percutaneous nephrolithotomy for struvite stones were identified. Of these, 7 had pure struvite stones (Group 1), 32 had mixed struvite stones (Group 2), both with metabolic evaluation, and 17 had pure struvite stones without metabolic evaluation (Group 3). The frequency of metabolic abnormalities and stone activity (defined as stone growth or stone-related events) was compared between groups. The median age was 55 years and 64 % were female. No significant difference in race, infection history, family history, stone location or volume existed between groups. Metabolic abnormalities were found in 57 % of Group 1 and 81 % of Group 2 patients. A similar proportion of Group 1 and 2 patients received modification to or continuation of metabolic therapy, whereas no Group 3 patients received any directed therapy. In patients with >6 months follow-up, the stone activity rate between Groups 1 and 2 appeared similar whereas Group 3 trended towards higher stone activity rate. Metabolic abnormalities in pure struvite stone formers appear to be more common than previously reported. Directed medical therapy in these patients may reduce stone activity. The role of metabolic evaluation and directed medical therapy needs reconsideration in patients with pure struvite stones.
Literature
2.
go back to reference Griffith DP, Musher DM (1973) Prevention of infected urinary stones by urease inhibition. Invest Urol 11(3):228–233PubMed Griffith DP, Musher DM (1973) Prevention of infected urinary stones by urease inhibition. Invest Urol 11(3):228–233PubMed
3.
go back to reference Patterson DE, Segura JW, LeRoy AJ (1987) Long-term follow-up of patients treated by percutaneous ultrasonic lithotripsy for struvite staghorn calculi. J Endourol/Endourol Soc 1(3):177–180CrossRef Patterson DE, Segura JW, LeRoy AJ (1987) Long-term follow-up of patients treated by percutaneous ultrasonic lithotripsy for struvite staghorn calculi. J Endourol/Endourol Soc 1(3):177–180CrossRef
4.
go back to reference Streem SB (1995) Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol 153(3 Pt 1):584–587CrossRefPubMed Streem SB (1995) Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol 153(3 Pt 1):584–587CrossRefPubMed
5.
go back to reference Cohen TD, Preminger GM (1996) Struvite calculi. Semin Nephrol 16(5):425–434PubMed Cohen TD, Preminger GM (1996) Struvite calculi. Semin Nephrol 16(5):425–434PubMed
6.
go back to reference Lerner SP, Gleeson MJ, Griffith DP (1989) Infection stones. J Urol 141(3 Pt 2):753–758PubMed Lerner SP, Gleeson MJ, Griffith DP (1989) Infection stones. J Urol 141(3 Pt 2):753–758PubMed
7.
go back to reference Iqbal MW, Youssef RF, Neisius A, Kuntz N, Hanna J, Ferrandino MN, Preminger GM, Lipkin ME (2013) Contemporary management of struvite stones using combined endourologic and medical treatment: predictors of unfavorable clinical outcome. J Endourol/Endourol Soc. doi:10.1089/end.2013.0257 Iqbal MW, Youssef RF, Neisius A, Kuntz N, Hanna J, Ferrandino MN, Preminger GM, Lipkin ME (2013) Contemporary management of struvite stones using combined endourologic and medical treatment: predictors of unfavorable clinical outcome. J Endourol/Endourol Soc. doi:10.​1089/​end.​2013.​0257
8.
go back to reference Lingeman JE, Siegel YI, Steele B (1995) Metabolic evaluation of infected renal lithiasis: clinical relevance. J Endourol/Endourol Soc 9(1):51–54CrossRef Lingeman JE, Siegel YI, Steele B (1995) Metabolic evaluation of infected renal lithiasis: clinical relevance. J Endourol/Endourol Soc 9(1):51–54CrossRef
9.
go back to reference Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N (1991) Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 20(3):243–247PubMed Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N (1991) Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol 20(3):243–247PubMed
11.
go back to reference Griffith DP, Khonsari F, Skurnick JH, James KE (1988) A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 140(2):318–324PubMed Griffith DP, Khonsari F, Skurnick JH, James KE (1988) A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 140(2):318–324PubMed
13.
go back to reference Resnick MI (1981) Evaluation and management of infection stones. Urol Clin North Am 8(2):265–276PubMed Resnick MI (1981) Evaluation and management of infection stones. Urol Clin North Am 8(2):265–276PubMed
14.
go back to reference Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS Jr (2005) Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol 173(6):1991–2000CrossRefPubMed Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS Jr (2005) Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol 173(6):1991–2000CrossRefPubMed
15.
go back to reference Resnick MI, Boyce WH (1980) Bilateral staghorn calculi–patient evaluation and management. J Urol 123(3):338–341PubMed Resnick MI, Boyce WH (1980) Bilateral staghorn calculi–patient evaluation and management. J Urol 123(3):338–341PubMed
16.
go back to reference Wall I, Hellgren E, Larsson L, Tiselius HG (1986) Biochemical risk factors in patients with renal staghorn stone disease. Urology 28(5):377–380CrossRefPubMed Wall I, Hellgren E, Larsson L, Tiselius HG (1986) Biochemical risk factors in patients with renal staghorn stone disease. Urology 28(5):377–380CrossRefPubMed
17.
go back to reference Silverman DE, Stamey TA (1983) Management of infection stones: the Stanford experience. Medicine 62(1):44–51CrossRefPubMed Silverman DE, Stamey TA (1983) Management of infection stones: the Stanford experience. Medicine 62(1):44–51CrossRefPubMed
19.
go back to reference Gettman MT, Segura JW (1999) Struvite stones: diagnosis and current treatment concepts. J Endourol/Endourol Soc 13(9):653–658CrossRef Gettman MT, Segura JW (1999) Struvite stones: diagnosis and current treatment concepts. J Endourol/Endourol Soc 13(9):653–658CrossRef
22.
go back to reference Iqbal MW, Akhter S, Khawaja MA (2008) Urinary metabolic abnormalities in idiopathic calcium oxalate stone formers: a single center study. Can J Pure Appl Sci (CJPAS) 2(1):139–142 Iqbal MW, Akhter S, Khawaja MA (2008) Urinary metabolic abnormalities in idiopathic calcium oxalate stone formers: a single center study. Can J Pure Appl Sci (CJPAS) 2(1):139–142
23.
go back to reference Schwartz BF, Bruce J, Leslie S, Stoller ML (2001) Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol/Endourol Soc 15(3):233–235CrossRef Schwartz BF, Bruce J, Leslie S, Stoller ML (2001) Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol/Endourol Soc 15(3):233–235CrossRef
24.
go back to reference Takeuchi H, Ueda M, Satoh M, Yoshida O (1991) Effects of dietary calcium, magnesium and phosphorus on the formation of struvite stones in the urinary tract of rats. Urol Res 19(5):305–308CrossRefPubMed Takeuchi H, Ueda M, Satoh M, Yoshida O (1991) Effects of dietary calcium, magnesium and phosphorus on the formation of struvite stones in the urinary tract of rats. Urol Res 19(5):305–308CrossRefPubMed
25.
go back to reference McLean RJ, Downey J, Clapham L, Nickel JC (1990) Influence of chondroitin sulfate, heparin sulfate, and citrate on Proteus mirabilis-induced struvite crystallization in vitro. J Urol 144(5):1267–1271PubMed McLean RJ, Downey J, Clapham L, Nickel JC (1990) Influence of chondroitin sulfate, heparin sulfate, and citrate on Proteus mirabilis-induced struvite crystallization in vitro. J Urol 144(5):1267–1271PubMed
26.
go back to reference Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17(5):308–315CrossRefPubMed Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17(5):308–315CrossRefPubMed
27.
go back to reference Elliot JS, Sharp RF, Lewis L (1959) The solubility of struvite in urine. J Urol 81(3):366–368PubMed Elliot JS, Sharp RF, Lewis L (1959) The solubility of struvite in urine. J Urol 81(3):366–368PubMed
29.
Metadata
Title
Should metabolic evaluation be performed in patients with struvite stones?
Authors
Muhammad Waqas Iqbal
Richard H. Shin
Ramy F. Youssef
Adam G. Kaplan
Fernando J. Cabrera
Jonathan Hanna
Charles D. Scales Jr.
Michael N. Ferrandino
Glenn M. Preminger
Michael E. Lipkin
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 2/2017
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-016-0893-6

Other articles of this Issue 2/2017

Urolithiasis 2/2017 Go to the issue